pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Thalidomide and its derivatives lenalidomide and pomalidomide (IMiDs) are effective treatments of haematologic malignancies. It was shown that IMiDs impart gain-of-function properties to the CUL4-RBX1-DDB1-CRBN (CRL4 CRBN ) ubiquitin ligase that enable binding, ubiquitination and degradation of key therapeutic targets such as IKZF1, IKZF3 and CSNK1A1. While these substrates have been implicated as efficacy targets in multiple myeloma (MM) and 5q deletion associated myelodysplastic syndrome (del(5q)-MDS), other targets likely exist. Using a pulse-chase SILAC mass spectrometry-based proteomics approach, we demonstrate that lenalidomide induces the ubiquitination and degradation of ZFP91. We establish ZFP91 as a bona fide IMiD-dependent CRL4 CRBN substrate and further show that ZFP91 harbours a zinc finger (ZnF) motif, related to the IKZF1/3 ZnF, critical for IMiD-dependent CRBN binding. These findings demonstrate that single time point pulse-chase SILAC mass spectrometry-based proteomics (pSILAC MS) is a sensitive approach for target identification of small molecules inducing selective protein degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“proteome-wide mass-spectrometry demonstrated selective degradation of endogenous IKZF1/3, and ZFP91 in multiple cell lines (3, 4, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide, lenalidomide and pomalidomide mediate CRL4CRBN-dependent degradation of a larger number of proteins than previously appreciated through a C2H2 ZF degron (3, 4, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous work has implicated the second C2H2 ZF domain in IKZF1 and IKZF3 (5, 7), and ZF4 of ZFP91 as the drug-inducible degrons (5, 7, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Cox, J., & Mann, M. (2008) · Nature Biotechnology · doi:10.1038/nbt.1511 · Cited by 14,855
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Ong, S.-E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A., & Mann, M. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m200025-mcp200 · Cited by 5,574
McCarthy, D. J., Chen, Y., & Smyth, G. K. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks042 · Cited by 5,195
Komander, D., & Rape, M. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060310-170328 · Cited by 3,679
RING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679
Cited by
Items 101–192 of 192
SimPLIT: Simplified Sample Preparation for Large-Scale Isobaric Tagging Proteomics
Sialana, F. J., Roumeliotis, T. I., Bouguenina, H., Hak, L. C. W., Wang, H., Caldwell, J., Collins, I., Chopra, R., & Choudhary, J. S. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00092 · Cited by 21
Jia, X., Pan, L., Zhu, M., Hu, H., Zhai, L., Liu, J., Hu, M., Liu, B., & Tan, M. (2019) · Journal of Proteomics · doi:10.1016/j.jprot.2019.103545 · Cited by 21
Cullin-RING Ligase 4 in Cancer: Structure, Functions, and Mechanisms
Cheng, J., Bin, X., & Tang, Z. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189169 · Cited by 20
Wilms, G., Schofield, K., Maddern, S., Foley, C., Shaw, Y., Smith, B. E., Basantes, L. E., Schwandt, K., Babendreyer, A., Chavez, T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01130 · Cited by 19
Exploration of degrons and their ability to mediate targeted protein degradation
Harris, T. J., & Trader, D. J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00787e · Cited by 19
PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates
Shimizu, N., Asatsuma‐Okumura, T., Yamamoto, J., Yamaguchi, Y., Handa, H., & Ito, T. (2021) · Communications Biology · doi:10.1038/s42003-021-02801-y · Cited by 19
Xu, Y., Zhao, W., Nie, H., Wang, J., Fu, J., Hu, H., Liu, Z., Tao, S., Zhang, M., Zhou, Y., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202505053 · Cited by 17
Raisch, J., Dubois, M., Groleau, M., Lévesque, D., Bürger, T., Jurkovic, C.-M., Brailly, R., Marbach, G., McKenna, A., Barrette, C., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100644 · Cited by 16
Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma
Chen, L., & Gooding, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1038329 · Cited by 16
The emerging role of targeted protein degradation to treat and study cancer
Brodermann, M. H., Henderson, E. K., & Sellar, R. S. (2024) · The Journal of Pathology · doi:10.1002/path.6301 · Cited by 16
Identification of novel GSPT1 degraders by virtual screening and bioassay
Zhang, S., Nie, S., Ma, G., Shen, M., Kong, L., Zuo, Z., & Li, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116524 · Cited by 16
Pillman, K. A., Scheer, K. G., Hackett-Jones, E., Saunders, K., Bert, A. G., Toubia, J., Whitfield, H. J., Sapkota, S., Sourdin, L., Pham, V., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz664 · Cited by 15
Proteomic strategies for characterizing ubiquitin-like modifications
Li, C., Nelson, T., Vertegaal, A. C. O., & Thibault, P. (2021) · Nature Reviews Methods Primers · doi:10.1038/s43586-021-00048-9 · Cited by 15
Emerging mechanisms of targeted protein degradation by molecular glues
Frere, G. A., de Araujo, E. D., & Gunning, P. T. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2022.01.001 · Cited by 14
Development of Dual and Selective Degraders of Cyclin‐Dependent Kinases 4 and 6
Jiang, B., Wang, E. S., Donovan, K. A., Liang, Y., Fischer, E. S., Zhang, T., & Gray, N. S. (2019) · Angewandte Chemie · doi:10.1002/ange.201901336 · Cited by 14
Self-citationDong, X., Han, Y., Zhang, E., Wang, Y., Zhang, P., Wang, C., Zhong, L., & Li, Q. (2021) · Aging · doi:10.18632/aging.202823 · Cited by 14
Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide
Zhou, L., Huang, X., Niesvizky, R., Pu, Z., & Xu, G. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000818 · Cited by 14
iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
Bouguenina, H., Nicolaou, S., Bihan, Y. L., Bowling, E. A., Calderon, C., Caldwell, J. J., Harrington, B., Hayes, A., McAndrew, C., Mitsopoulos, C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107059 · Cited by 13
Targeting the ubiquitin pathway in lymphoid malignancies
Li, B., Eichhorn, P. J. A., & Chng, W. J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216978 · Cited by 13
Extrapolating Lessons from Targeted Protein Degradation to Other Proximity-Inducing Drugs
Winter, G. E. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00191 · Cited by 13
Exploring the Rampant Expansion of Ubiquitin Proteomics
Rose, A., & Mayor, T. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8706-1_22 · Cited by 13
A double-edged sword of neo-substrate degradation in PROTACs
Song, Z., Duan, C., Wu, M., Wang, Z., Pan, Y., Zhang, C., Huang, W., & Zeng, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118253 · Cited by 12
IMiDs induce FAM83F degradation via an interaction with CK1α to attenuate Wnt signalling
Dunbar, K. J., Macartney, T., & Sapkota, G. P. (2020) · Life Science Alliance · doi:10.26508/lsa.202000804 · Cited by 12
Targeting the Dark Lipid Kinase PIP4K2C with a Potent and Selective Binder and Degrader
Teng, M., Jiang, J., Wang, E. S., Geng, Q., Toenjes, S. T., Donovan, K. A., Mageed, N., Yue, H., Nowak, R. P., Wang, J., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202302364 · Cited by 11
Self-citationSafety considerations for cereblon-recruiting targeted protein degraders
Garside, H., Aslamkhan, A. G., Daniels, D. L., Datta, K., Pedersen, M. E., Hukkanen, R. R., Jones, L. H., Ketter, N., Lahoti, T. S., Loberg, L. I., et al. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01426-2 · Cited by 11
Yang, X., He, Y., Kim, R. D., Fleming, J. B., & Xie, H. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00782-2 · Cited by 11
Perspectives on the Development of First-in-Class Protein Degraders
Rambacher, K. M., Calabrese, M. F., & Yamaguchi, M. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0033 · Cited by 11
Zhang, X., Dhruv, H., Deng, Q., Tudor, M., Bechtel, N., Nagilla, R., Jolivette, L. J., Rice, C., Orth, P., Behshad, E., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00668 · Cited by 10
Discovery of Novel Potent Triple IKZF1/2/3 Degraders for the Treatment of Hematological Cancers
Wei, T., Sun, S., Hu, X., Wei, P., Fan, Z., Yan, J. W., Wang, Y., Qi, Z., Jia, C., Mao, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01086 · Cited by 9
Zhou, L., Yu, W.-J., Jayabalan, D. S., Niesvizky, R., Jaffrey, S. R., Huang, X., & Xu, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.605989 · Cited by 9
Discovery of a Novel Potent and Orally Efficacious PROTAC Degrader of HPK1 for Tumor Immunotherapy
Tong, J., Wang, K., Liu, C., Wang, L., Miao, Q., Wu, Y., Zhang, Z., Liao, Z., Jiang, S., Wang, R., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00970 · Cited by 8
Chen, L., Aleman, A., Larráyoz, M., Chiu, H., Zhao, J., Oekelen, O. V., Kelly, G., Kim‐Schulze, S., Laganà, A., Jagannath, S., et al. (2026) · Blood · doi:10.1182/blood.2025030891 · Cited by 8
Differential Analysis of Cereblon Neosubstrates in Rabbit Embryos Using Targeted Proteomics
Federspiel, J. D., Catlin, N. R., Nowland, W. S., Stethem, C. M., Mathialagan, N., Ocaña, M. F., & Bowman, C. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100797 · Cited by 8
Yu, H. H., Reitsma, J. M., Sweredoski, M. J., Moradian, A., Hess, S. Y., & Deshaies, R. J. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/595389 · Cited by 8
Yamada, K., Yamanaka, S., Yamakoshi, H., Kohyama, A., Iwabuchi, Y., Kosako, H., & Sawasaki, T. (2025) · Communications Biology · doi:10.1038/s42003-025-08761-x · Cited by 7
Targeted Protein Degradation: Principles, Strategies, and Applications
He, T., Wen, C., Yang, G., & Yang, X. (2023) · Advanced Biology · doi:10.1002/adbi.202300083 · Cited by 7
Methods to characterize and discover molecular degraders in cells
Lin, Z., & Woo, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00261b · Cited by 7
Design and Applications of Bifunctional Small Molecules in Biology
Boyd, S. R., Chang, L., de Rezende, W. C., Raji, I. O., Kandel, P., Holmes, S. L., & Young, D. W. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140534 · Cited by 7
Methods to Study the Molecular Mechanism and Drive the Design of Protein Degraders
Crowe, C., & Ciulli, A. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00800 · Cited by 6
Li, L., Liu, S., & Luo, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116394 · Cited by 6
Hung, C.-L., Hsu, W.-N., Wang, T.-C., Chen, W., Chen, Y., Kuo, Z., Hu, T.-L., Lin, Y.-C., Yeh, H.-H., Lin, H.-C., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101253 · Cited by 5
Profiling CELMoD-Mediated Degradation of Cereblon Neosubstrates
Thompson, J. W., Clayton, T., Khambatta, G., Bateman, L. A., Carroll, C. W., Chamberlain, P. P., & Matyskiela, M. E. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_15 · Cited by 5
Cereblon-Targeting Ligase Degraders in Myeloma
Lee, H., Neri, P. E., & Bahlis, N. J. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.01.001 · Cited by 5
The Contribution of Native Protein Complexes to Targeted Protein Degradation
Glennie, L., Curnutt, N., Sathe, G. J., Chatelier, B. L., Goff, F., Zhao, J.-F., Cartwright, T. N., Dunbar, K. J., Wood, N. T., Macartney, T., et al. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00098 · Cited by 5
Structure-Based Design of CBP/EP300 Degraders: When Cooperativity Overcomes Affinity
Cheng‐Sánchez, I., Gosselé, K. A., Palaferri, L., Laul, E., Riccabella, G., Bedi, R. K., Li, Y., Müller, A., Corbeski, I., Caflisch, A., et al. (2024) · JACS Au · doi:10.1021/jacsau.4c00292 · Cited by 6
Zhang, R., Zheng, Y., Xiang, F., & Zhou, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116756 · Cited by 5
Development of CDK2 and CDK5 Dual Degrader TMX‐2172
Teng, M., Jiang, J., He, Z., Kwiatkowski, N. P., Donovan, K. A., Mills, C. E., Victor, C., Hatcher, J. M., Fischer, E. S., Sorger, P. K., et al. (2020) · Angewandte Chemie · doi:10.1002/ange.202004087 · Cited by 5
Self-citationXu, Y., Zhao, W., Nie, H., Wang, J., Fu, J., Hu, H., Liu, Z., Tao, S., Zhang, M., Zhou, Y., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202505053 · Cited by 4
Meli, R., Aksoy, O., Vallet, S., Slade, D., & Podar, K. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2482557 · Cited by 3
Yin, H., Lang, S., Lu, Y., Zhou, Z., Ren, S., Yu, X., Qiu, J., Li, Z., Wang, X., Peng, L., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-09213-2 · Cited by 3
Li, Y., Wilson, A., Chrisochoidou, Y., Martin, S., Bird, S. A., Morales, S., Leiro, M., Kozik, Z., Crump, N. T., Roumeliotis, T. I., et al. (2026) · Haematologica · doi:10.3324/haematol.2025.288024 · Cited by 3
Proteome-wide identification of the druggable CRBN interactome
Galli, P., Xiao, S., Meng, Y., Hanzl, A., Bendel, A. M., Baur, R., Aguirre, J. D., Díaz-Rovira, A. M., Stammnitz, M. R., Kempf, G., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03237-7 · Cited by 3
Lin, Z., Zhang, Y., Liu, X., Luo, H., Li, Q., Gao, Q., Wang, X., Wen, J., Li, L., Yu, F., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19468 · Cited by 3
Evolving CRBN ligands enhance the drug-like properties of protein degraders
Ji, X.-Q., Wang, L., & Dai, X. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2700038 · Cited by 2
Liu, Y., Chen, L., Peng, B., Zeng, P., Cao, L., Huang, L., Zhou, L., Yang, S., Wang, J., Sun, Y., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.1973691 · Cited by 2
Thalidomide – From a Banned Drug to Molecular Glues, PROTACs, and New Concepts in Drug Discovery
Yamamoto, J., Handa, H., & Yamaguchi, Y. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch24 · Cited by 2
Transcriptional profiles define drug refractory disease in myeloma
Zhu, Y. X., Bruins, L. A., Chen, X., Shi, C., de Campos, C. B., Meurice, N., Wang, X., Ahmann, G. J., Ramsower, C. A., Braggio, E., et al. (2022) · eJHaem · doi:10.1002/jha2.455 · Cited by 2
Targeting the Dark Lipid Kinase PIP4K2C with a Potent and Selective Binder and Degrader
Teng, M., Jiang, J., Wang, E. S., Geng, Q., Toenjes, S. T., Donovan, K. A., Mageed, N., Yue, H., Nowak, R. P., Wang, J., et al. (2023) · Angewandte Chemie · doi:10.1002/ange.202302364 · Cited by 2
Self-citationProteomics‐Driven Strategies for Proximity‐Inducing Drug Discovery
Fan, R., Ni, J., Zhou, T., Jiang, H. Q., Zhao, W., & Tan, M. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.3307512 · Cited by 1
Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy
Wei Min, N. I., Garg, S., Chowdhury, B., Sattler, M., Sanchez, D., Meng, C., Akatsu, T., Donovan, K. A., Qi, J., Wang, M. Y., et al. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.200952 · Cited by 1
Self-citationTargeting Sigma-2 Receptor and ZFP91 in Pancreatic Cancer
Hanafi, M. S. A. A. (2021) · Deep Blue (University of Michigan) · doi:10.7302/1515 · Cited by 1
Haldar, S. D. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Yu, H. H. (2019) · CaltechTHESIS (California Institute of Technology) · doi:10.7907/z7pk-nh81
Investigating the Mechanism and Species-Specificity of Thalidomide Derivatives
Fink, E. C. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Protein Degradation Inducers SNIPERs and Protacs against Oncogenic Proteins
Shibata, N., Ohoka, N., Hattori, T., & Naito, M. (2019) · doi:10.1201/9780429295034-16
Dubois, M. (2019) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke)
Identification and Characterization of Novel Cullin 4-based E3 Ligases in Somatic Cell Division
Gilberto, S. (2017) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-b-000219014
New Activities of CELMoDs, Cereblon E3 Ligase-modulating Drugs
Matyskiela, M. E., Clayton, T., Thompson, J. W., Carroll, C. W., Bateman, L. A., LeBrun, L. A., & Chamberlain, P. P. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00094
Study of hypoxia driven pancreatic cancer development
Gupta, N. (2019) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/139818
Copeland, R. A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733651684.793549798
Mechanistic Basis and Role of Immunomodulatory Drugs
Gribben, J. G. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch25
Targeted protein degradation using thalidomide and its derivatives
Yamanaka, S. (2024) · Translational and Regulatory Sciences · doi:10.33611/trs.2024-007
Research Progress of IMiDs as PPI Stabilizer in Protein Degradation
宋, 冰. (2025) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2025.131006
Rengel, B. D. (2021) · Lume (Universidade Federal do Rio Grande do Sul)
Exploring the Features and Challenges of Proteolysis Targeting Chimera (PROTAC) Development
You, I. (2023) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Michon, M., Curpanen, S., Pessey, O., Thaï, R., Gaillard, J., Herbette, G., Hinsinger, K., Gillet, D., Armengaud, J., Cintrat, J., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118645
Pakdaman, F. (2026) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/32109
Wang, K., Kenny, S., Chagan, Z., Li, L., Das, C., & Liu, X. (2026) · Structure · doi:10.1016/j.str.2026.02.015
近接ビオチン化法を基盤とした細胞表面および薬剤により誘導されるタンパク質間相互作用解析に関する研究
山田, 航. (2025) · Institutional Repositories DataBase (IRDB)
Genome-wide screening identifies ZFP91 as a key regulator of EVI1 in myeloid leukemia
Hayashida, H., Masamoto, Y., Oyama, T., Hino, T., Morita, K., Fujiki, K., Nakato, R., Shirahige, K., & Kurokawa, M. (2026) · Oncogene · doi:10.1038/s41388-026-03727-7
Proteomics‐Driven Strategies for Proximity‐Inducing Drug Discovery
Fan, R., Ni, J., Zhou, T., Jiang, H. Q., Zhao, W., & Tan, M. (2026) · Angewandte Chemie · doi:10.1002/ange.3307512
Liu, Y., Chen, L., Peng, B., Zeng, P., Cao, L., Huang, L., Zhou, L., Yang, S., Wang, J., Sun, Y., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.1973691
A patenting perspective of IKZF2 molecular glue degraders (2020-present)
Zhang, X. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2748593
Recent advances in the development of tag-targeted protein degradation systems
Li, B., Lu, Y., Che, J., & Dong, X. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2742479
BindingDB Entry 50002775: Inducing protein-protein interactions with molecular glues.
BindingDB (2020) · UC San Diego · doi:10.7270/q21g0px4
BindingDB (2022) · UC San Diego · doi:10.7270/q2qn6bfx
Umeta, L. T., Mallareddy, J. R., Singh, S., Vishwakarma, K., Kizhake, S., Wu, W., Kizhake, A. G., Boghean, L., Vishwakarma, S., Kachhia, M., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00632-z
Metadata
- Authors
- An, J., Ponthier, C. M., Sack, R., Seebacher, J., Stadler, M. B., Donovan, K. A., & Fischer, E. S.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Friedrich Miescher Institute (CH)
- SIB Swiss Institute of Bioinformatics (CH)
- Corresponding author
- Fischer, Eric S.
- Venue
- Nature Communications
- Published
- 2017-05-22
- Volume
- 8
- Issue
- 1
- Pages
- 15398-15398
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5458144
- OpenAlex
- W2618306819
- Cited by
- 176
- References
- 51
- Citations by year
- 2026: 17 · 2025: 16 · 2024: 24 · 2023: 11 · 2022: 16 · 2021: 26 · 2020: 26 · 2019: 20 · 2018: 19 · 2017: 1
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fisher Center for Alzheimer's Research Foundation
- SystemsX.ch
- National Institutes of Health
- National Cancer Institute (R01CA214608)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Keywords
- lenalidomide, immunomodulators, cereblon, ubiquitination, protein degradation, zinc finger, multiple myeloma, selective protein degradation, drug target identification
- MeSH terms
- Lenalidomide, Animals, Antineoplastic Agents, Humans, Multiple Myeloma, Myelodysplastic Syndromes, Peptide Hydrolases, Mass Spectrometry, Substrate Specificity, Zinc Fingers, Gene Deletion, Amino Acid Motifs, Ubiquitin, Proteomics, Ubiquitin-Protein Ligases, HCT116 Cells, Adaptor Proteins, Signal Transducing, Mice, Receptors, Interleukin-17, Ubiquitination, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.